TG Therapeutics | TGTX - Current Assets


TG Therapeutics reported $630.76M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Alaunos Therapeutics USD 1.99M 697K Dec/2025
Amgen USD 31.48B 2.42B Mar/2026
Ardelyx USD 381.87M 447K Mar/2026
Arrowhead Research USD 1.17B 223.75M Dec/2025
Bayer EUR 32.91B 30M Dec/2025
Biogen USD 9.19B 216.3M Mar/2026
Corcept Therapeutics USD 426.03M 59.43M Mar/2026
Curis USD 6.92M 7.5M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Infinity Pharmaceuticals USD 19.91M 8.46M Jun/2023
J&J USD 59.17B 3.55B Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Novartis USD 26.61B 3.85B Mar/2026
Novavax USD 978.28M 3.69M Dec/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
TG Therapeutics USD 630.76M 31M Dec/2025
Verastem USD 223.41M 69.36M Dec/2025
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026